{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.95"},{"groupId":"OG001","spread":"0","value":"1.24"},{"groupId":"OG002","spread":"0.28","value":"0.71"},{"groupId":"OG003","spread":"0.48","value":"0.87"},{"groupId":"OG004","spread":"0.18","value":"0.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Week 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"1.02"},{"groupId":"OG001","spread":"0.49","value":"1.31"},{"groupId":"OG002","spread":"0.19","value":"0.75"},{"groupId":"OG003","spread":"0.65","value":"0.92"},{"groupId":"OG004","spread":"0.10","value":"0.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.35","value":"0.92"},{"groupId":"OG001","spread":"0.01","value":"1.43"},{"groupId":"OG002","spread":"0.38","value":"0.97"},{"groupId":"OG003","spread":"0.33","value":"0.79"},{"groupId":"OG004","spread":"0","value":"1.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"1.15"},{"groupId":"OG001","spread":"0.34","value":"1.42"},{"groupId":"OG002","spread":"0.35","value":"0.83"},{"groupId":"OG003","spread":"0.74","value":"1.12"},{"groupId":"OG004","spread":"35.73","value":"26.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"1.07"},{"groupId":"OG001","spread":"0.54","value":"1.37"},{"groupId":"OG002","spread":"0.34","value":"0.79"},{"groupId":"OG003","spread":"0.40","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"1.57"},{"groupId":"OG001","spread":"0.83","value":"1.81"},{"groupId":"OG002","spread":"0.35","value":"0.83"},{"groupId":"OG003","spread":"0.60","value":"1.26"},{"groupId":"OG004","spread":"0","value":"0.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Week 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"The cytokine was quantitated using V-PLEX Human Proinflammatory Panel, a multiplex immunoassay kit developed by Meso Scale Diagnostics (MSD). A four-parameter logistic fit calibration curve was generated and used to calculate concentrations in tested samples. Analyses were performed at pre-treatment and 1 week following the first dose of drug and additionally at 2, 3, 6, and 9 weeks following the course 1 drug dose if feasible. The mean concentration of TNF-alpha in pg/ml was reported with a standard deviation. When only one patient was analyzed, the standard deviation was reported as 0 (rather than undefined).","dispersionType":"Standard Deviation","groups":[{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.1 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 1, Dose Level 1"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 1, Dose Level 2"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG002","title":"Stratum 1, Dose Level 3"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG003","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG004","title":"Stratum 2, Dose Level 3"}],"paramType":"MEAN","populationDescription":"Not all patients had data available at every time point.","reportingStatus":"POSTED","timeFrame":"Pre-treatment (week 0), 1 week, 2 week, 3 weeks, 6 weeks and 9 weeks post-treatment","title":"Concentration of the Cytokine Tumor Necrosis Factor-alpha (TNF-alpha)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"pg/ml"}